Literature DB >> 15907648

Fentanyl.

Theodore H Stanley1.   

Abstract

Fentanyl, a potent lipid-soluble opioid which was first synthesized more than 40 years ago, is still the most popular opioid used in the perioperative period throughout the world. Fentanyl's introduction, versatility, and popularity have resulted in its use in many acute and chronic pain conditions and a multitude of novel delivery systems in the last two decades. In spite of the development of more potent, safer, faster onset, and both shorter and longer lasting alternative opioids, fentanyl remains the mainstay of anesthesiologists and Certified Registered Nurse Anesthetists in the perioperative period, and for many pain physicians throughout the world.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907648     DOI: 10.1016/j.jpainsymman.2005.01.009

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  15 in total

1.  Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers.

Authors:  Mona Darwish; Kenneth Tempero; Mary Kirby; Jeffrey Thompson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

3.  Bidirectional effects of fentanyl on dendritic spines and AMPA receptors depend upon the internalization of mu opioid receptors.

Authors:  Hang Lin; Paul Higgins; Horace H Loh; Ping-Yee Law; Dezhi Liao
Journal:  Neuropsychopharmacology       Date:  2009-03-18       Impact factor: 7.853

4.  Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy.

Authors:  Mona Darwish; Ehab Hamed; John Messina
Journal:  Perspect Medicin Chem       Date:  2010-06-04

Review 5.  Fentanyl for the treatment of tumor-related breakthrough pain.

Authors:  Helmar Bornemann-Cimenti; Mischa Wejbora; Istvan S Szilagyi; Andreas Sandner-Kiesling
Journal:  Dtsch Arztebl Int       Date:  2013-04-19       Impact factor: 5.594

Review 6.  An overview of clinical and commercial impact of drug delivery systems.

Authors:  Aaron C Anselmo; Samir Mitragotri
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

7.  Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury.

Authors:  Simonetta Papa; Raffaele Ferrari; Massimiliano De Paola; Filippo Rossi; Alessandro Mariani; Ilaria Caron; Eliana Sammali; Marco Peviani; Valentina Dell'Oro; Claudio Colombo; Massimo Morbidelli; Gianluigi Forloni; Giuseppe Perale; Davide Moscatelli; Pietro Veglianese
Journal:  J Control Release       Date:  2013-11-10       Impact factor: 9.776

8.  Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects.

Authors:  Mona Darwish; Mary Kirby; John G Jiang; William Tracewell; Philmore Robertson
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

9.  Effect of fentanyl versus buprenorphine on the pupil size in phacoemulsification cataract surgery.

Authors:  Abdolreza Najafi Anaraki; Abbas Akrami; Niloofar Motamed; Elham Seydali
Journal:  Saudi J Anaesth       Date:  2012-07

10.  Anticipation of distress after discontinuation of mechanical ventilation in the ICU at the end of life.

Authors:  E J O Kompanje; B van der Hoven; J Bakker
Journal:  Intensive Care Med       Date:  2008-05-31       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.